跳至主要内容
临床试验/NCT01210248
NCT01210248Unknown不适用

Correlation Between CYP2C19 Genotype, Level Of Clopidogrel Metabolite And Platelet Inhibition Status

Assaf-Harofeh Medical Center1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2010年9月最近更新:
适应症

试验速览

阶段
不适用
入组人数
500
试验地点
1

研究概览

简要总结

The aim of this study is to check correlation between CYP2C19 genotype level of clopidogrel metabolite in plasma and platelet inhibition status.

详细描述

THE FIRST PHASE OF THE RESEARCH WILL INVOLVE PATIENTS RECRUITMENT AND INFORMED CONSENT FOR GENETIC TESTING.THE MAJORITY OF PATIENTS WILL BE RECRUITED FROM EMERGENCY DEPARTMENT. EVERY PATIENT WILL BE ASKED ABOUT HIS AND HIS PARENT'S ETHNICITY (ASHKENASI OR SEPHARDY JEW) AND ADDITIONAL DRUGS HE TAKES. IF PATIENT AGREES TO PARTICIPATE IN THE STUDY , HIS BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS:

  1. GENETIC (FOR CYP450 2C19)
  2. PLATELET MAPPING TEST ( BY THROMBOELASTOGRAPH ASSAY)
  3. CLOPIDOGREL INACTIVE METABOLITE DETERMINATION BY CHROMATOGRAPHIC METHOD

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • > 18 OLD PATIENTS
  • THAT TAKE CLOPIDOGREL MORE THAN 1 WEEK

排除标准

  • PREGNANCY
  • CHRONIC LIVER DISEASES

研究者

申办方类型
Other Gov

研究点 (1)

Loading locations...

相似试验